Search
Aminobenzoic acid
go.drugbank.com/drugs/DB02362ApprovedWithdrawnA member of the vitamin B complex. It used to be common in sunscreening agents until found to also be a sensitizer. The potassium salt is used therapeutically in fibrotic skin disorders.
Dasatinib
go.drugbank.com/drugs/DB01254ApprovedInvestigational[A2226] The use of dasatinib was first approved by the FDA in 2006.[L45171,L45186] … BCR-ABL is associated with the uncontrolled activity of the ABL tyrosine kinase and is involved in the pathogenesis of CML and 15-30% of ALL cases.
Oxcarbazepine
go.drugbank.com/drugs/DB00776ApprovedInvestigationalto its primarily reductive metabolism. … - a pro-drug of the more active (S)-enantiomer is also marketed as a separate anti-epileptic under the name [eslicarbazepine].
Janssen COVID-19 Vaccine
go.drugbank.com/drugs/DB15857ApprovedInvestigationalAs of June 2020, a Phase 1/2 clinical trial in adult humans was announced to evaluate the safety, immunogenicity, and efficacy of the ad26.COV.S vaccine in 1045 healthy adults between the ages of 18-55 … The Janssen COVID-19 vaccine is available under an Emergency Use Authorization (EUA) in the US.[L41745]
Rusfertide
go.drugbank.com/drugs/DB17724ApprovedInvestigational[L64098] The FDA approved rusfertide on August 28, 2026 for the treatment of erythrocytosis in adults with polycythemia vera, a blood cancer. … [L64098] It is a synthetic cyclic peptide that blocks the iron transporter ferroportin, reducing the availability of iron for red blood cell production and lowering hematocrit.
Omacetaxine mepesuccinate
go.drugbank.com/drugs/DB04865ApprovedInvestigationalWithdrawnThen in March 2006, it received Orphan Drug status from the FDA for the treatment of CML. … In November 2006, omacetaxine mepesuccinate, for the treatment of CML, was granted Fast Track designation by the FDA.
Synonyms: mepesuccinato de omacetaxinaApomorphine
go.drugbank.com/drugs/DB00714ApprovedInvestigationalApomorphine is a non-ergoline dopamine D2 agonist indicated to treat hypomobility associated with Parkinson's. It was first synthesized in 1845 and first used in Parkinson's disease in 1884.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin Receptor AntagonistsSynonyms: (6aR)-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol, (R)-5,6,6a,7-tetrahydro-6-methyl-4H-dibenzo[de,g]quinoline-10,11-diolPamidronic acid
go.drugbank.com/drugs/DB00282ApprovedInvestigationalPamidronic acid is a second generation, nitrogen containing bisphosphonate similar to [neridronic acid] and [alendronic acid].[A203111] Pamidronic acid was first described in the literature in 1977. … [A203267] The second generation bisphosphonates are less common as third generation bisphosphonates, such as [ibandronic acid], [zoledronic acid], [minodronic acid], and [risedronic acid] are becoming
Irinotecan
go.drugbank.com/drugs/DB00762ApprovedInvestigationalThis leads to the arrest of the cell cycle in the S-G2 phase and cancer cell death.[A263376] … [A263376] The bis-piperidine side chain in the structure of irinotecan bestows enhanced water solubility.
Products: CLORHIDRATO DE IRINOTECAN TRIHIDRATO 20 MG/MLDarolutamide
go.drugbank.com/drugs/DB12941ApprovedInvestigationalDarolutamide is a nonsteroidal androgen receptor antagonist for the treatment of castrate-resistant, non-metastatic prostate cancer (nmCRPC). … This condition occurs in the majority of patients with advanced prostate cancer who have been treated with androgen receptor antagonists.
Categories: Androgen Receptor Inhibitors